If it is granted, AMBS will have 3 orphan designations. One in P2 and 2 entering P1 by late 2015 or early 2016. Eltoprazine in P2 for LID and P3 for ADHD. Diagnostic Division with first revenue milestone about to occur. Doesn't sound like a 0.08 stock to me. A very modest amount of revenue or a grant will unlock value across the portfolio and the price should rise quite aggressively.